Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gynecology

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 171 articles:
HTML format



Single Articles


    December 2025
  1. NASH Z, Christmas M, Gronlund T, Hickey M, et al
    Top ten menopause research priorities.
    Lancet. 2025;404:2535-2536.
    PubMed    


    February 2025
  2. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    PubMed     Abstract available


  3. HUGHES H
    Endometriosis: an Australian perspective on encouraging change.
    Lancet. 2025;405:378-379.
    PubMed    


  4. DANG L, Mi M, Qiao Y, Zhu L, et al
    Eliminating cervical cancer in the Tibetan Plateau.
    Lancet. 2025;405:375-376.
    PubMed    


    November 2024
  5. LORUSSO D, Yamada K, Li K, Cerrotta A, et al
    Pembrolizumab for locally advanced cervical cancer - Authors' reply.
    Lancet. 2024;404:2051-2052.
    PubMed    


  6. DONG B, Lu Y, Wang Y, Sun P, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050.
    PubMed    


  7. SCHMID MP, Petric P, Mahantshetty U, Kirisits C, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050-2051.
    PubMed    


  8. KAMRAVA M, Beriwal S
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049.
    PubMed    


  9. MURAKAMI N, Okonogi N, Terao Y, Shikama N, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049-2050.
    PubMed    



  10. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed     Abstract available


    October 2024
  11. MCCORMACK M, Eminowicz G, Gallardo D, Diez P, et al
    Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    Lancet. 2024;404:1525-1535.
    PubMed     Abstract available


  12. DUSKA LR, Randall LM
    Progress in the treatment paradigms for locally advanced cervical cancer.
    Lancet. 2024;404:1494-1496.
    PubMed    


  13. WU X, Sun Y, Yang H, Wang J, et al
    Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
    Lancet. 2024 Oct 15:S0140-6736(24)02135-4. doi: 10.1016/S0140-6736(24)02135.
    PubMed     Abstract available


  14. SUN C, Ma D
    Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2024 Oct 15:S0140-6736(24)02196-2. doi: 10.1016/S0140-6736(24)02196.
    PubMed    


  15. THE LANCET
    Endometriosis: addressing the roots of slow progress.
    Lancet. 2024;404:1279.
    PubMed    


    September 2024
  16. SHARP G, Randhawa A, Fernando AN
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01710-0. doi: 10.1016/S0140-6736(24)01710.
    PubMed    


  17. BROWN L, Hunter MS, Crandall CJ, Connors HJ, et al
    Reflections on The Lancet menopause Series - Authors' reply.
    Lancet. 2024 Sep 25:S0140-6736(24)01712-4. doi: 10.1016/S0140-6736(24)01712.
    PubMed    


  18. STUCKEY BGA
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01709-4. doi: 10.1016/S0140-6736(24)01709.
    PubMed    


  19. XIAO Y, Shen M, Chen X
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01711-2. doi: 10.1016/S0140-6736(24)01711.
    PubMed    


  20. GENNIGENS C
    Hope emerging in the locally advanced cervical cancer landscape.
    Lancet. 2024 Sep 13:S0140-6736(24)01918-4. doi: 10.1016/S0140-6736(24)01918.
    PubMed    


  21. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-
    Lancet. 2024 Sep 13:S0140-6736(24)01808-7. doi: 10.1016/S0140-6736(24)01808.
    PubMed     Abstract available


    August 2024
  22. RYDELIUS J, Hognert H, Kopp-Kallner H, Brandell K, et al
    First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024;404:864-873.
    PubMed     Abstract available


  23. MOSESON H, Gerdts C
    Expanding access, reducing burdens, and improving person-centred care in abortion.
    Lancet. 2024;404:826-827.
    PubMed    


  24. FIGUERAS F, Rial-Crestelo M, Gratacos E
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial - Authors' reply.
    Lancet. 2024;404:751-752.
    PubMed    


  25. GILES-CLARK HJ, Rolnik DL, Hodges RJ, Skinner SM, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750.
    PubMed    


  26. BACON I, Hezelgrave NL, Cerdeira AS, Mylrea-Foley B, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750-751.
    PubMed    


  27. KAMIHARA Y, Nagase H, Ishikawa H
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749-750.
    PubMed    


  28. MEIJERINK L, Terstappen F, Depmann M, Bekker M, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749.
    PubMed    


  29. BORNSTEIN E, Vintzileos A
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:748-749.
    PubMed    


  30. WEI F, Georges D, Man I, Baussano I, et al
    Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.
    Lancet. 2024;404:435-444.
    PubMed     Abstract available


  31. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    PubMed    


    July 2024
  32. ALVES L
    New abortion bill in Brazil sparks backlash.
    Lancet. 2024;404:17.
    PubMed    


    June 2024
  33. HO VNA, Pham TD, Nguyen NT, Wang R, et al
    Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.
    Lancet. 2024 Jun 26:S0140-6736(24)00756-6. doi: 10.1016/S0140-6736(24)00756.
    PubMed     Abstract available


  34. JAFFE S
    US Supreme Court protects access to abortion medication.
    Lancet. 2024;403:2679-2680.
    PubMed    


  35. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    PubMed     Abstract available


  36. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    PubMed     Abstract available


    May 2024
  37. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    PubMed     Abstract available


  38. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    PubMed    


    April 2024
  39. STRAND TA, McCann A, Kvestad I, Chandyo RK, et al
    Vitamin B12 deficiency in pregnant women - Authors' reply.
    Lancet. 2024;403:1450.
    PubMed    


  40. SEN S
    Vitamin B12 deficiency in pregnant women.
    Lancet. 2024;403:1449-1450.
    PubMed    


    March 2024
  41. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    PubMed     Abstract available


  42. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    PubMed    


  43. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
    Lancet. 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
    PubMed     Abstract available


  44. TEWARI KS, Monk BJ
    Immunotherapy plus chemoradiotherapy in cervical cancer management.
    Lancet. 2024 Mar 20:S0140-6736(24)00468-9. doi: 10.1016/S0140-6736(24)00468.
    PubMed    


  45. HEISLER M, Mitchell N, Arey W, Erenberg M, et al
    US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies.
    Lancet. 2024 Mar 19:S0140-6736(24)00551-8. doi: 10.1016/S0140-6736(24)00551.
    PubMed    


  46. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
    Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
    Lancet. 2024;403:1081-1082.
    PubMed    


  47. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
    Optimising health after early menopause.
    Lancet. 2024;403:958-968.
    PubMed     Abstract available


  48. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available


  49. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
    Promoting good mental health over the menopause transition.
    Lancet. 2024;403:969-983.
    PubMed     Abstract available


  50. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
    An empowerment model for managing menopause.
    Lancet. 2024;403:947-957.
    PubMed     Abstract available


  51. HAWKES P, Scott J, Hickey M
    500 Strong: celebrating older women's bodies in menopause and beyond.
    Lancet. 2024;403:894-903.
    PubMed    


  52. SAMARASEKERA U
    Martha Hickey: responding to the complexity of menopause.
    Lancet. 2024;403:893.
    PubMed    


  53. THE LANCET
    Time for a balanced conversation about menopause.
    Lancet. 2024;403:877.
    PubMed    


  54. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    PubMed     Abstract available


  55. ZAROCOSTAS J
    Renewed calls to scale-up cervical cancer screening.
    Lancet. 2024;403:797.
    PubMed    


    February 2024
  56. PETERS RPH, Klausner JD, Mazzola L, Mdingi MM, et al
    Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
    Lancet. 2024;403:657-664.
    PubMed     Abstract available


  57. THORNTON J
    Reducing patchiness in abortion care in the UK.
    Lancet. 2024 Feb 15:S0140-6736(24)00312-X. doi: 10.1016/S0140-6736(24)00312.
    PubMed    


  58. HURRELL A, Webster L, Sparkes J, Battersby C, et al
    Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.
    Lancet. 2024 Feb 8:S0140-6736(23)02357-7. doi: 10.1016/S0140-6736(23)02357.
    PubMed     Abstract available


  59. CERDEIRA AS, Karumanchi SA
    Serial placental growth factor-based testing in pre-eclampsia.
    Lancet. 2024 Feb 8:S0140-6736(23)02578-3. doi: 10.1016/S0140-6736(23)02578.
    PubMed    


  60. LUCAS N, Rex S, Devroe S
    Treatment modalities for placenta accreta spectrum.
    Lancet. 2024;403:437.
    PubMed    


  61. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    Treatment modalities for placenta accreta spectrum - Authors' reply.
    Lancet. 2024;403:437-438.
    PubMed    


    January 2024
  62. KAMYA MR, Kakuru A, Dorsey G
    Dihydroartemisinin-piperaquine for prevention of malaria in pregnant women living with HIV.
    Lancet. 2024 Jan 12:S0140-6736(24)00048-5. doi: 10.1016/S0140-6736(24)00048.
    PubMed    


  63. BARSOSIO HC, Madanitsa M, Ondieki ED, Dodd J, et al
    Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
    Lancet. 2024 Jan 12:S0140-6736(23)02631-4. doi: 10.1016/S0140-6736(23)02631.
    PubMed     Abstract available


  64. RIAL-CRESTELO M, Lubusky M, Parra-Cordero M, Krofta L, et al
    Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Jan 11:S0140-6736(23)02228-6. doi: 10.1016/S0140-6736(23)02228.
    PubMed     Abstract available


  65. ELNAKIB S, Fair M, Mayrhofer E, Afifi M, et al
    Pregnant women in Gaza require urgent protection.
    Lancet. 2024 Jan 11:S0140-6736(23)02835-0. doi: 10.1016/S0140-6736(23)02835.
    PubMed    


    December 2023
  66. CHAILLET N, Masse B, Grobman WA, Shorten A, et al
    Perinatal morbidity among women with a previous caesarean delivery (PRISMA trial): a cluster-randomised trial.
    Lancet. 2023 Dec 11:S0140-6736(23)01855-X. doi: 10.1016/S0140-6736(23)01855.
    PubMed     Abstract available


  67. OAKNIN A, Gladieff L, Martinez-Garcia J, Villacampa G, et al
    Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
    Lancet. 2023 Dec 1:S0140-6736(23)02405-4. doi: 10.1016/S0140-6736(23)02405.
    PubMed     Abstract available


  68. MILESHKIN LR, Manoharan S
    Improving survival from metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2023 Dec 1:S0140-6736(23)02690-9. doi: 10.1016/S0140-6736(23)02690.
    PubMed    


    November 2023
  69. ADEPOJU P
    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.
    PubMed    


  70. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available


  71. HOBSON G, Dennis N
    Experiences of menopause in the Welsh NHS workplace: a focus group study.
    Lancet. 2023;402 Suppl 1:S51.
    PubMed     Abstract available


  72. JONG FC, Kotzur M, Amiri R, Ling J, et al
    Using a participatory approach to encourage uptake of breast, colorectal, and cervical cancer screening for Scottish Muslim women: a pilot qualitative study.
    Lancet. 2023;402 Suppl 1:S12.
    PubMed     Abstract available


  73. COWLING A, Nevens L, Contogiorgi N, Bradley N, et al
    Developing and piloting an intervention to reduce colposcopy non-attendance and corresponding inequalities: a mixed-methods study.
    Lancet. 2023;402 Suppl 1:S35.
    PubMed     Abstract available


    October 2023
  74. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    PubMed    


  75. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available


  76. BHAN N, McDougal L
    Centring agency and norms to meet the health needs of pregnant adolescents.
    Lancet. 2023 Oct 11:S0140-6736(23)02226-2. doi: 10.1016/S0140-6736(23)02226.
    PubMed    


  77. SABET F, Prost A, Rahmanian S, Al Qudah H, et al
    The forgotten girls: the state of evidence for health interventions for pregnant adolescents and their newborns in low-income and middle-income countries.
    Lancet. 2023 Oct 11:S0140-6736(23)01682-3. doi: 10.1016/S0140-6736(23)01682.
    PubMed     Abstract available


    August 2023
  78. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.
    PubMed    


  79. JAFFE S
    Abortion foes threaten PEPFAR.
    Lancet. 2023;402:598.
    PubMed    


  80. CAHILL EP
    Adding a COX-2 inhibitor improves efficacy of emergency contraception.
    Lancet. 2023 Aug 16:S0140-6736(23)01612-4. doi: 10.1016/S0140-6736(23)01612.
    PubMed    


  81. LI RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, et al
    Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
    Lancet. 2023 Aug 16:S0140-6736(23)01240-0. doi: 10.1016/S0140-6736(23)01240.
    PubMed     Abstract available


    July 2023
  82. DASGUPTA N, Ajazi EM, Schwartz TA, Marshall SW, et al
    Misclassification of overdose events in the X:BOT study.
    Lancet. 2023 Jul 19:S0140-6736(23)00113-7. doi: 10.1016/S0140-6736(23)00113.
    PubMed    


  83. SABBAH N, Demar M, Sogbo F, Zappa M, et al
    Recurrent vomiting and confusion in pregnancy: hypercalcaemia due to parathyroid adenoma.
    Lancet. 2023;402:62-63.
    PubMed    


  84. STRANDELL A, Hellgren M
    Time to stop routine prescription of low-molecular-weight heparin to women with recurrent pregnancy loss and inherited thrombophilia.
    Lancet. 2023;402:6-7.
    PubMed    


    June 2023
  85. CLUVER CA, Walker SP
    Early delivery for pre-eclampsia might save lives in low-income and middle-income settings.
    Lancet. 2023 Jun 29:S0140-6736(23)00824-3. doi: 10.1016/S0140-6736(23)00824.
    PubMed    


  86. BEARDMORE-GRAY A, Vousden N, Seed PT, Vwalika B, et al
    Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
    Lancet. 2023 Jun 29:S0140-6736(23)00688-8. doi: 10.1016/S0140-6736(23)00688.
    PubMed     Abstract available


  87. LUCAS DN, Bamber JH, Quasim S
    Perinatal outcomes and the role of obstetric anaesthesia interventions.
    Lancet. 2023;401:2038-2039.
    PubMed    


  88. QUENBY S, Booth K, Hiller L, Coomarasamy A, et al
    Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
    Lancet. 2023 Jun 1:S0140-6736(23)00693-1. doi: 10.1016/S0140-6736(23)00693.
    PubMed     Abstract available


    May 2023
  89. SHAHEEN-HUSSAIN S, Lombard A, Basile S
    Confronting medical colonialism and obstetric violence in Canada.
    Lancet. 2023;401:1763-1765.
    PubMed    


  90. MCCURRY J
    Japan approves abortion pill.
    Lancet. 2023;401:1558.
    PubMed    


  91. MOHIDDIN A, Semrau KEA, Simon J, Langlois EV, et al
    The ethical, economic, and developmental imperative to prevent small vulnerable newborns and stillbirths: essential actions to improve the country and global response.
    Lancet. 2023 May 5:S0140-6736(23)00721-3. doi: 10.1016/S0140-6736(23)00721.
    PubMed    


    April 2023
  92. HEISLER M, Cox-Toure T, Kaufman R
    US abortion bans violate patients' right to information and to health.
    Lancet. 2023 Apr 24:S0140-6736(23)00808-5. doi: 10.1016/S0140-6736(23)00808.
    PubMed    


  93. JAFFE S
    Drug developers caution against US mifepristone ban.
    Lancet. 2023;401:1325-1326.
    PubMed    


  94. SHAND AW, Kidson-Gerber GL
    Anaemia in pregnancy: a major global health problem.
    Lancet. 2023 Apr 20:S0140-6736(23)00396-3. doi: 10.1016/S0140-6736(23)00396.
    PubMed    


  95. PASRICHA SR, Mwangi MN, Moya E, Ataide R, et al
    Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00278-7. doi: 10.1016/S0140-6736(23)00278.
    PubMed     Abstract available


  96. CHANDYO RK, Kvestad I, Ulak M, Ranjitkar S, et al
    The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial.
    Lancet. 2023 Apr 6:S0140-6736(23)00346-X. doi: 10.1016/S0140-6736(23)00346.
    PubMed     Abstract available


    March 2023
  97. BERGH C, Lundin K
    No benefit to pregnancy or livebirth by time-lapse-based embryo selection in IVF.
    Lancet. 2023 Mar 30:S0140-6736(23)00219-2. doi: 10.1016/S0140-6736(23)00219.
    PubMed    


  98. LEDERMAN S, Ottery FD, Cano A, Santoro N, et al
    Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
    Lancet. 2023 Mar 13:S0140-6736(23)00085-5. doi: 10.1016/S0140-6736(23)00085.
    PubMed     Abstract available


  99. PRAGUE JK
    Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.
    Lancet. 2023 Mar 13:S0140-6736(23)00353-7. doi: 10.1016/S0140-6736(23)00353.
    PubMed    


  100. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    A planned caesarean hysterectomy for placenta accreta spectrum at 35 weeks of gestation: antenatal identification and a multidisciplinary approach to manage an increasing condition.
    Lancet. 2023;401:856-857.
    PubMed    


  101. CLUVER C, de Groot C, Mol BW, Murphy KE, et al
    The need for appropriate language in the debate on medicalisation of pregnancy.
    Lancet. 2023;401:818-819.
    PubMed    


  102. KAKURU A, Jagannathan P
    Can we reduce malaria in pregnancy and improve birth outcomes?
    Lancet. 2023 Mar 10:S0140-6736(23)00101-0. doi: 10.1016/S0140-6736(23)00101.
    PubMed    


  103. MADANITSA M, Barsosio HC, Minja DTR, Mtove G, et al
    Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlle
    Lancet. 2023 Mar 10:S0140-6736(22)02535-1. doi: 10.1016/S0140-6736(22)02535.
    PubMed     Abstract available


  104. HAWKES S, Kedia S, Odunga S, Dahal M, et al
    From flowers to menstrual-flow trackers: the corporatisation of women's equality and wellbeing.
    Lancet. 2023 Mar 7:S0140-6736(23)00456-7. doi: 10.1016/S0140-6736(23)00456.
    PubMed    


    February 2023
  105. MURRAY CJL
    A systematic analysis points in the wrong direction for cervical cancer elimination - Author's reply.
    Lancet. 2023;401:555-556.
    PubMed    


  106. JACKSON A
    A systematic analysis points in the wrong direction for cervical cancer elimination.
    Lancet. 2023;401:555.
    PubMed    


  107. DUGOFF L
    The use of cell-free DNA technology in pregnancy loss.
    Lancet. 2023 Feb 1:S0140-6736(23)00182-4. doi: 10.1016/S0140-6736(23)00182.
    PubMed    


  108. SCHLAIKJAER HARTWIG T, Ambye L, Gruhn JR, Petersen JF, et al
    Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
    Lancet. 2023 Feb 1:S0140-6736(22)02610-1. doi: 10.1016/S0140-6736(22)02610.
    PubMed     Abstract available


  109. HORNE AW, Tong S, Moakes CA, Middleton LJ, et al
    Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2023 Feb 1:S0140-6736(22)02478-3. doi: 10.1016/S0140-6736(22)02478.
    PubMed     Abstract available


  110. SONALKAR S, Gilmore E
    A fresh look at treatment for ectopic pregnancy.
    Lancet. 2023 Feb 1:S0140-6736(23)00181-2. doi: 10.1016/S0140-6736(23)00181.
    PubMed    


    January 2023
  111. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    PubMed    


  112. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    PubMed     Abstract available


    December 2022
  113. SHEIKH J, Allotey J, Kew T, Fernandez-Felix BM, et al
    Effects of race and ethnicity on perinatal outcomes in high-income and upper-middle-income countries: an individual participant data meta-analysis of 2 198 655 pregnancies.
    Lancet. 2022;400:2049-2062.
    PubMed     Abstract available


    November 2022
  114. SAITO M, McGready R, Tinto H, Rouamba T, et al
    Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.
    Lancet. 2022 Nov 25:S0140-6736(22)01881-5. doi: 10.1016/S0140-6736(22)01881.
    PubMed     Abstract available


  115. SLUTSKER L, Leke RGF
    First-trimester use of ACTs for malaria treatment in pregnancy.
    Lancet. 2022 Nov 25:S0140-6736(22)02166-3. doi: 10.1016/S0140-6736(22)02166.
    PubMed    


  116. OLAJIDE N, Robb K, Niedzwiedz C, Jani B, et al
    Cervical cancer risk factors in eight west African countries: cross-sectional analysis of the demographic and health survey 2017-20.
    Lancet. 2022;400 Suppl 1:S68.
    PubMed     Abstract available


  117. ANDREAE G, Scott S, Nguyen G, Bell Z, et al
    Food insecurity among pregnant women living in high-income countries: a systematic review.
    Lancet. 2022;400 Suppl 1:S17.
    PubMed     Abstract available


    October 2022
  118. DASHRAATH P, Thong WSE, Ang M, Lee YM, et al
    Interferon shrinks spleen in pregnant patient with myeloproliferative neoplasm.
    Lancet. 2022;400:e11.
    PubMed    


  119. BAUD D, Nielsen-Saines K, Mattar C, Musso D, et al
    Monkeypox exposure during pregnancy: what does UK public health guidance advise? - Authors' reply.
    Lancet. 2022;400:1509-1510.
    PubMed    


  120. ADLER H, Taggart R
    Monkeypox exposure during pregnancy: what does UK public health guidance advise?
    Lancet. 2022;400:1509.
    PubMed    


  121. VAN LENNEP JER, Nerenberg KA
    Delivering evidence to prevent recurrent venous thromboembolism in pregnancy.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02030.
    PubMed    


  122. BISTERVELS IM, Buchmuller A, Wiegers HMG, Ni Ainle F, et al
    Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02128.
    PubMed     Abstract available


  123. HODGETTS MORTON V, Toozs-Hobson P, Moakes CA, Middleton L, et al
    Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.
    Lancet. 2022;400:1426-1436.
    PubMed     Abstract available


  124. GLYDE T
    LGBTQIA+ menopause: room for improvement.
    Lancet. 2022 Oct 18. pii: S0140-6736(22)01935.
    PubMed    


  125. KHALIL A, Samara A, Ladhani S, O'Brien P, et al
    Monkeypox and pregnancy: time for global surveillance and prevention strategies.
    Lancet. 2022;400:1193.
    PubMed    


    September 2022
  126. DONNEZ J, Taylor HS, Stewart EA, Bradley L, et al
    Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Lancet. 2022;400:896-907.
    PubMed     Abstract available


  127. DE LANGE ME, Huirne JAF
    Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding.
    Lancet. 2022;400:866-867.
    PubMed    


    August 2022
  128. ENDLER M, Petro G, Gemzell Danielsson K, Grossman D, et al
    A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
    Lancet. 2022;400:670-679.
    PubMed     Abstract available


  129. WINIKOFF B, Lohr PA
    Randomised trials of medical abortion provide some but not all the answers.
    Lancet. 2022;400:638-639.
    PubMed    


  130. ROBERTS SL, Kendall GS, Edwards S, Pandya P, et al
    Screening policies for cytomegalovirus in pregnancy in the era of antivirals.
    Lancet. 2022;400:489-490.
    PubMed    


    July 2022
  131. HAAKENSTAD A, Angelino O, Irvine CMS, Bhutta ZA, et al
    Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022;400:295-327.
    PubMed     Abstract available


  132. PRADHAN MR
    Contraceptive mix and informed choice.
    Lancet. 2022;400:255-257.
    PubMed    


  133. JAFFE S
    "Chaos" for patients and providers after US abortion ruling.
    Lancet. 2022;400:85-86.
    PubMed    


  134. HIAM L, Mateescu I, Spiegel P
    Improving access to contraception and abortion in Romania in the context of the conflict in Ukraine.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)01275.
    PubMed    


  135. JAFFE S
    Federal abortion rights end, but not legal challenges.
    Lancet. 2022;400:13-14.
    PubMed    


    June 2022
  136. DASHRAATH P, Nielsen-Saines K, Mattar C, Musso D, et al
    Guidelines for pregnant individuals with monkeypox virus exposure.
    Lancet. 2022 Jun 21. pii: S0140-6736(22)01063.
    PubMed    


  137. GIUDICE LC, As-Sanie S, Arjona Ferreira JC, Becker CM, et al
    Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Lancet. 2022;399:2267-2279.
    PubMed     Abstract available


  138. SARASWAT L, Bhattacharya S
    Relugolix combination therapy for endometriosis pain.
    Lancet. 2022;399:2244-2245.
    PubMed    


  139. HOLT E
    Poland to introduce controversial pregnancy register.
    Lancet. 2022;399:2256.
    PubMed    


  140. THE LANCET
    Attitudes towards menopause: time for change.
    Lancet. 2022;399:2243.
    PubMed    


  141. O'BRIEN E, Rich M
    Obstetric violence in historical perspective.
    Lancet. 2022;399:2183-2185.
    PubMed    


  142. REED SD, Zhou X, Ichikawa L, Gatz JL, et al
    Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.
    Lancet. 2022;399:2103-2112.
    PubMed     Abstract available


  143. BARTZ D
    Incidence of perforation with intrauterine devices.
    Lancet. 2022;399:2076-2077.
    PubMed    


    May 2022
  144. SCHAEDEL Z, Rymer J
    Menopause care and over the counter vaginal oestradiol.
    Lancet. 2022 May 31. pii: S0140-6736(22)00952.
    PubMed    


  145. JARDINE J, Harris T, Khalil A, van der Meulen J, et al
    Adverse pregnancy outcomes: biological essentialism versus embodied biology - Authors' reply.
    Lancet. 2022;399:2014.
    PubMed    


  146. RAVI K, Janiak E
    Adverse pregnancy outcomes: biological essentialism versus embodied biology.
    Lancet. 2022;399:2013-2014.
    PubMed    


  147. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    PubMed    


  148. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    PubMed    


  149. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    PubMed    


  150. JAFFE S
    Health organizations fear effects of US abortion ruling.
    Lancet. 2022;399:1854.
    PubMed    


  151. VOSS FO, van Beurden M, Jordanova ES
    Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia.
    Lancet. 2022;399:1755-1757.
    PubMed    


  152. TRUTNOVSKY G, Reich O, Joura EA, Holter M, et al
    Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2022;399:1790-1798.
    PubMed     Abstract available


  153. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
    Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
    Lancet. 2022;399:1809.
    PubMed    


    April 2022
  154. MAKONI M
    Hope for access to abortion in Kenya.
    Lancet. 2022;399:1456.
    PubMed    


  155. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
    Endometrial cancer.
    Lancet. 2022;399:1412-1428.
    PubMed     Abstract available


    March 2022
  156. BOOTH A
    Activists welcome Colombia's decriminalisation of abortion.
    Lancet. 2022;399:899.
    PubMed    


  157. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    PubMed    


    February 2022
  158. PASHANKAR R, Prabulos AM, Feder HM Jr
    A woman pregnant with twins has fever, haemolysis, and thrombocytopenia caused by babesiosis: could be confused with HELLP syndrome.
    Lancet. 2022;399:e10.
    PubMed    


  159. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    PubMed    


  160. GERSHENSON DM, Miller A, Brady WE, Paul J, et al
    Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
    Lancet. 2022;399:541-553.
    PubMed     Abstract available


  161. BLAGDEN SP
    Targeting MAPK in recurrent, low-grade serous ovarian cancer.
    Lancet. 2022;399:499-501.
    PubMed    


  162. CERDEIRA AS, Ismail L, Moore N, George B, et al
    Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences.
    Lancet. 2022;399:554.
    PubMed    


    January 2022
  163. HUG L, You D, Blencowe H, Moran AC, et al
    Strengthening the reporting of stillbirths globally - Authors' reply.
    Lancet. 2022;399:142.
    PubMed    


  164. DAS AM, Janardhanan R
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:141.
    PubMed    


  165. JOOS O, Swiney C, Sferrazza L
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:140-141.
    PubMed    


    December 2021
  166. JAFFE S
    US Supreme Court expected to weaken abortion rights.
    Lancet. 2021;398:2137-2138.
    PubMed    


    November 2021
  167. SANSON C, Majer M, Pautier P, Gouy S, et al
    Unexplained uterine atrophy following neoadjuvant chemotherapy in fertility sparing management of cervical cancer.
    Lancet. 2021;398:e17.
    PubMed    


  168. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    PubMed     Abstract available


  169. CRUICKSHANK ME, Grigore M
    Cervical cancers avoided by HPV immunisation.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02396.
    PubMed    


  170. JARDINE J, Walker K, Gurol-Urganci I, Webster K, et al
    Adverse pregnancy outcomes attributable to socioeconomic and ethnic inequalities in England: a national cohort study.
    Lancet. 2021 Nov 1. pii: S0140-6736(21)01595.
    PubMed     Abstract available


    October 2021
  171. THE LANCET
    Abortion bans in the USA harm health equity.
    Lancet. 2021;398:1461.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.